# Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

> **NCT03763929** · PHASE2 · TERMINATED · sponsor: **Diffusion Pharmaceuticals Inc** · enrollment: 6 (actual)

## Conditions studied

- Stroke, Acute

## Interventions

- **DRUG:** Trans-Sodium Crocetinate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03763929
- **Lead sponsor:** Diffusion Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-22
- **Primary completion:** 2020-10-19
- **Final completion:** 2020-10-19
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was stopped due to lack of meaningful enrollment due to the COVID-19 pandemic.
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763929, "Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03763929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*